These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 12540202

  • 1. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.
    Haga JH, Jennings LK, Slack SM.
    Ann Biomed Eng; 2002; 30(10):1262-72. PubMed ID: 12540202
    [Abstract] [Full Text] [Related]

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
    Goto S, Tamura N, Li M, Handa M, Ikeda Y, Handa S, Ruggeri ZM.
    J Thromb Haemost; 2003 Sep 17; 1(9):2022-30. PubMed ID: 12941046
    [Abstract] [Full Text] [Related]

  • 5. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 17; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 6. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ.
    J Thromb Thrombolysis; 2002 Aug 17; 14(1):15-24. PubMed ID: 12652146
    [Abstract] [Full Text] [Related]

  • 7. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR.
    Crit Care Med; 2002 May 17; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [Abstract] [Full Text] [Related]

  • 8. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ, Broderick TM, Roth EM, Whang D, Mueller M, Lacock P, Anderson LC, Howard W, Blanck C, Schneider J, Abbottsmith CA.
    J Thromb Thrombolysis; 2000 Feb 17; 9(2):149-55. PubMed ID: 10613996
    [Abstract] [Full Text] [Related]

  • 9. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Feb 17; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 10. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
    Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, Michelson AD.
    Am J Cardiol; 2003 Nov 01; 92(9):1099-101. PubMed ID: 14583364
    [Abstract] [Full Text] [Related]

  • 11. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
    Lev EI, Osende JI, Richard MF, Robbins JA, Delfin JA, Rodriguez O, Sharma SK, Jayasundera T, Badimon JJ, Marmur JD.
    J Am Coll Cardiol; 2001 Mar 01; 37(3):847-55. PubMed ID: 11693761
    [Abstract] [Full Text] [Related]

  • 12. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS.
    Coron Artery Dis; 1998 Mar 01; 9(9):603-16. PubMed ID: 9861523
    [No Abstract] [Full Text] [Related]

  • 13. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
    Schrör K.
    Herz; 2001 Apr 01; 26 Suppl 1():30-5. PubMed ID: 11349624
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
    Li Y, Spencer FA, Ball S, Becker RC.
    J Thromb Thrombolysis; 2000 Aug 01; 10(1):69-76. PubMed ID: 10947916
    [Abstract] [Full Text] [Related]

  • 15. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
    Pontiggia L, Steiner B, Ulrichts H, Deckmyn H, Forestier M, Beer JH.
    Thromb Haemost; 2006 Dec 01; 96(6):774-80. PubMed ID: 17139372
    [Abstract] [Full Text] [Related]

  • 16. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA, Bozarth JM, Forsythe MS, Slee A.
    Cardiovasc Res; 2000 Sep 01; 47(4):819-26. PubMed ID: 10974231
    [Abstract] [Full Text] [Related]

  • 17. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
    Caron A, Théorêt JF, Mousa SA, Merhi Y.
    J Cardiovasc Pharmacol; 2002 Aug 15; 40(2):296-306. PubMed ID: 12131559
    [Abstract] [Full Text] [Related]

  • 20. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S, Lassila R.
    Thromb Res; 2006 Aug 15; 117(3):291-7. PubMed ID: 15878612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.